Edesa Biotech’s EB01 Shows Encouraging Interim Results In Dermatitis Trial
Edesa Biotech Inc’s (NASDAQ:EDSA) EB01 has met a key interim study parameter as part of an adaptive Phase 2b trial evaluating EB01 as…
VBL Therapeutics Stock Jumps on Adding PFS as Second Independent Primary Endpoint in Ovarian Cancer Gene Therapy Trial
VBL Therapeutics Ltd (NASDAQ:VBLT) has amended the primary endpoint in the OVAL Phase 3 registration-enabling study of VB-111 (ofranergene obadenovec) gene therapy for…
Tonix Pharma Fibromyalgia Treatment Associated with Improvement in Pain, Sleep, Fatigue
Tonix Pharmaceuticals Holding Corp (NASDAQ:TNXP) has announced the poster presentation of previously reported results from its Phase 3 RELIEF trial evaluating the TNX-102…
Updated Analysis Show Seagen’s Tukysa Extended Median OS to Two Years with Benefits Maintained in Breast Cancer
Seagen Inc (NASDAQ:SGEN) has announced that improvements in overall survival (OS) and progression-free survival (PFS) were maintained with long-term follow-up from…
The Daily Biotech Pulse: Merck Completes Organon Spin-Off, Auris Repositions As RNA Therapeutic Company With Trasir Purchase, Replimune’s Readout
Here's a roundup of top developments in the biotech space over the last 24 hours:
Scaling The Peaks
(Biotech Stocks Hitting 52-week Highs June 2)
A Breakthrough in Targeted Cancer Therapy: Lixte Biotechnology Clinical Stage Compound LB-100
Dr. John Kovach, the CEO and founder of Lixte Biotechnology Holdings, Inc., expressed excitement for his company’s first-in-class protein phosphatase inhibitor, LB-100 as a new addition to cancer treatment at the Benzinga Global Small Cap Business Conference on May 13, 2021.
Oric Pharma’s ORIC-101 Shows Tumor Regression, Prolonged Stable Disease in Multiple Heavily Pretreated Tumors
Oric Pharmaceuticals Inc (NASDAQ:ORIC) has announced initial data from an ongoing Phase 1b study evaluating ORIC-101 in combination with nab-paclitaxel, in…
Eli Lilly-Innovent Biologics Score Expanded Use Approval of Tyvyt n Lung Cancer Patients In China
The National Medical Products Administration (NMPA) of China has approved Innovent Biologics Inc (OTC:IVBXF) and Eli Lilly And Co’s (NYSE:LLY) Tyvyt (sintilimab injection)…
Oyster Point Pharma Announces Enriched Tear Film Gene Therapy
Oyster Point Pharma, Inc. (NASDAQ:OYST), a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of first-in-class therapies to treat ocular surface diseases, today
Monopar Announces New Drug Candidate, MNPR-202; Says Enters Into Collaboration Agreement With National University Of Singapore For Preclinical Evaluation In Cancer
Monopar Therapeutics Inc. (NASDAQ:MNPR), a clinical-stage biopharmaceutical company primarily focused on developing proprietary therapeutics designed to extend life or improve the quality of